- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05767346
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM)
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Cytokinetics MD
- Phone Number: 650-624-2929
- Email: medicalaffairs@cytokinetics.com
Study Locations
-
-
-
Québec, Canada
- Recruiting
- Institut universitaire de cardiologie et de pneumonlogie de Quebec - Universite Laval
-
-
-
-
-
Changsha, China
- Recruiting
- Xiangya Second Hospital of Central South University
-
Shanghai, China
- Recruiting
- Zhongshan Hospital Fudan University
-
Wuhan, China
- Recruiting
- Renmin Hospital of Wuhan University
-
Zhengzhou, China
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
-
-
-
-
Aarhus, Denmark
- Recruiting
- Aarhus University Hospital
-
Copenhagen, Denmark
- Recruiting
- Copenhagen University Hospital
-
-
-
-
-
Marseille, France
- Recruiting
- CHU La Timone
-
Paris, France
- Recruiting
- Hôpital Européen Georges Pompidou
-
Paris, France
- Recruiting
- Hopital Lariboisiere - APHP
-
Pessac, France
- Recruiting
- Hopital Cardiologique Haut Leveque - CHU de Bordeaux
-
Rennes, France
- Recruiting
- CHU Pontchaillou
-
Saint-Herblain, France
- Recruiting
- Hopital Laennec - CHU de Nantes
-
-
-
-
-
Berlin, Germany
- Recruiting
- Charite-Universitatsmedizin Berlin - Campus Virchow Klinikum
-
Jena, Germany
- Recruiting
- Universitaetsklinikum Jena
-
-
-
-
-
Budapest, Hungary
- Recruiting
- Semmelweis Egyetem, Városmajori Szív- és Érgyógyászati Klinika
-
-
-
-
-
Ashkelon, Israel
- Recruiting
- Barzilai Medical Center
-
Jerusalem, Israel
- Recruiting
- Hadassah Hebrew Medical Center- Ein Kerem
-
Ramat Gan, Israel
- Recruiting
- The Chaim Sheba Medical Center
-
Reẖovot, Israel
- Recruiting
- Kaplan Medical Center
-
Safed, Israel
- Recruiting
- Ziv Medical Center
-
-
-
-
-
Florence, Italy
- Recruiting
- AOU Careggi
-
-
-
-
-
Rotterdam, Netherlands
- Recruiting
- Erasmus Medical Center
-
-
-
-
-
A Coruña, Spain
- Recruiting
- Complejo Hospitalario Universitario A Coruna
-
Barcelona, Spain
- Recruiting
- Hospital Clinic de Barcelona
-
El Palmar, Spain
- Recruiting
- Hospital Clinico Universitario Virgen Arrixaca
-
Madrid, Spain
- Recruiting
- Hospital Universitario Puerta de Hierro
-
Salamanca, Spain
- Recruiting
- Hospital Universitario de Salamanca
-
Sevilla, Spain
- Recruiting
- Hospital Universitario Virgen del Rocio
-
Sevilla, Spain
- Recruiting
- Hospital Universitario Virgen Macarena
-
Son Ferriol, Spain
- Recruiting
- Hospital Universitario Son Llatzer
-
-
-
-
-
Glasgow, United Kingdom
- Recruiting
- NHS Greater Glasgow and Clyde
-
Liverpool, United Kingdom
- Recruiting
- Liverpool Heart and Chest Hospital NHS Foundation Trust
-
London, United Kingdom
- Recruiting
- Royal Brompton Hospital
-
London, United Kingdom
- Recruiting
- Barts Health NHS Trust
-
Oxford, United Kingdom
- Recruiting
- Oxford University Hospital NHS Trust - John Radcliffe Hospital - OCMR
-
-
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Recruiting
- Alaska Heart and Vascular Institute
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- UC San Diego Health - Sulpizio Cardiovascular Center
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center (Smidt Heart Institute)
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Recruiting
- Yale New Haven Hospital
-
-
Florida
-
Orlando, Florida, United States, 32804
- Recruiting
- AdventHealth
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory Clinic
-
Fayetteville, Georgia, United States, 30214
- Recruiting
- Piedmont Fayette Hospital
-
-
Illinois
-
Evanston, Illinois, United States, 60208
- Recruiting
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Burlington, Massachusetts, United States, 01803
- Recruiting
- Lahey Hospital & Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Recruiting
- Saint Luke's Hospital of Kansas City
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Morristown Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center/New York Presbyterian Hospital
-
-
North Carolina
-
Morrisville, North Carolina, United States, 27560
- Recruiting
- Duke Health Center Arringdon
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University
-
Portland, Oregon, United States, 97225
- Recruiting
- Providence St. Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Division of Heart Failure and Transplantation (Hospital of the University of Pennsylvania)
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University Medical Center
-
Nashville, Tennessee, United States, 37205
- Recruiting
- Ascension Saint Thomas Heart West
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Hospital
-
Houston, Texas, United States, 77030
- Recruiting
- CHI St. Luke's Health Baylor-St. Luke's Medical Center
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Intermountain Medical Center
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Recruiting
- Inova Schar Heart and Vascular
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants who meet all the following criteria at screening may be included in the trial:
- Males and females between 18 to 85 years of age, inclusive, at screening
- Body mass index < 35 kg/m2
Diagnosed with oHCM per the following criteria by cardiac magnetic resonance imaging (CMR) or echocardiography -
- Has left ventricular (LV) hypertrophy with non-dilated LV chamber in the absence of other cardiac disease and
Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory:
- ≥ 15 mm in one or more myocardial segments OR
- ≥ 13 mm in one or more wall segments and a known disease-causing gene mutation or positive family history of HCM
- NYHA class II or III
Has a screening echocardiogram with the following determined by the echocardiography core laboratory:
- Resting LVOT-G > 30 mm Hg and/or post-Valsalva LVOT-G ≥ 50 mmHg at screening AND
- LVEF ≥ 60%
- Hemoglobin ≥ 10g/dL
- Patients previously exposed to mavacamten are allowed to participate but must be off mavacamten for at least 8 weeks
Exclusion Criteria:
Any of the following criteria will exclude potential participants from the trial:
- Medical indication for either beta blocker or calcium-channel blockers prohibiting drug discontinuation other than oHCM
- History of intolerance or medical contraindication to beta blocker therapy
- Resting SBP of > 160 mmHg
- Resting heart rate of > 100 bpm
Significant valvular heart disease
- Moderate-severe valvular aortic stenosis or fixed subaortic obstruction
- Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator judgment)
- Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics oHCM (eg, Noonan syndrome, Fabry disease, amyloidosis)
- History of LV systolic dysfunction (LVEF < 45%) or stress cardiomyopathy at any time during their clinical course
- Inability to exercise on a treadmill or bicycle (eg, orthopedic limitations)
- Documented room air oxygen saturation reading < 90% at screening
- Planned septal reduction treatment that cannot be deferred during the trial period
- History of septal reduction therapy (surgical myectomy or alcohol septal ablation) within 6 months of screening
- History of paroxysmal or persistent atrial fibrillation or atrial flutter. Atrial flutter treated with radio frequency ablation without recurrence within the last 6 months prior to screening is allowed.
- Current or recent (< 4 weeks) therapy with disopyramide
- History of syncope, symptomatic ventricular arrhythmia, or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening
- Has received prior treatment with aficamten or previously intolerant (reduced LVEF requiring permanent drug discontinuation) to mavacamten
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aficamten up to 20 mg plus placebo for metoprolol
Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.
|
Aficamten (CK-3773274) tablets administered orally
Placebo for metoprolol succinate administered orally
|
Active Comparator: Metoprolol succinate up to 200 mg plus placebo for aficamten
Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.
|
Placebo for aficamten (CK-3773274) administered orally
Metoprolol succinate tablets administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET)
Time Frame: Baseline to Week 24
|
Effect of aficamten compared with metoprolol succinate on exercise capacity in patients with symptomatic oHCM
|
Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with ≥1 class improvement in New York Heart Association (NYHA) Functional Class
Time Frame: Baseline to Week 24
|
Effect of aficamten compared with metoprolol succinate on NYHA Functional Classification
|
Baseline to Week 24
|
Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Time Frame: Baseline to Week 24
|
Effect of aficamten compared with metoprolol succinate on patient health status
|
Baseline to Week 24
|
Change in left ventricular mass index (LVMI)
Time Frame: Baseline to Week 24
|
Effect of aficamten on mass of the heart as compared with metoprolol succinate
|
Baseline to Week 24
|
Change in left atrial volume index (LAVI)
Time Frame: Baseline to Week 24
|
Effect of aficamten on size of the heart as compared with metoprolol succinate
|
Baseline to Week 24
|
Change from baseline values in NT-proBNP from baseline to Week 24
Time Frame: Baseline to Week 24
|
Effect of CK-¬3773274 on NT-proBNP
|
Baseline to Week 24
|
Change in post-Valsalva LVOT-G from baseline to Week 24
Time Frame: Baseline to Week 24
|
Effect of aficamten on post-Valsalva LVOT-G
|
Baseline to Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Scientific Leadership, Cytokinetics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Hypertrophy
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
- CY 6032
- 2023-504809-37-00 (Other Identifier: EU CTR Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Hypertrophic Cardiomyopathy (oHCM)
-
Bristol-Myers SquibbNot yet recruitingObstructive Hypertrophic Cardiomyopathy (oHCM)Canada
-
CytokineticsJi Xing Pharmaceuticals (Shanghai) Co., Ltd.CompletedObstructive Hypertrophic Cardiomyopathy (oHCM)United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
SuZhou Sinus Medical Technologies Co.,LtdNot yet recruiting
-
Bristol-Myers SquibbActive, not recruitingHOCM, Hypertrophic Obstructive CardiomyopathyUnited States
-
Shaare Zedek Medical CenterMedtronicUnknownHOCM, Hypertrophic Obstructive Cardiomyopathy
-
Michele De BonisCompletedObstructive Hypertrophic Cardiomyopathy | Septal HypertrophyItaly
-
Hospital Clinic of BarcelonaUnknownHypertrophic Obstructive Cardiomyopathy (HOCM)Spain
Clinical Trials on Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
-
CytokineticsJi Xing Pharmaceuticals (Shanghai) Co., Ltd.CompletedObstructive Hypertrophic Cardiomyopathy (oHCM)United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
-
CytokineticsCompletedHypertrophic Cardiomyopathy (HCM)United States, Spain, Italy, Netherlands
-
CytokineticsEnrolling by invitationSymptomatic Hypertrophic Cardiomyopathy (HCM)United States, France, Israel, Spain, United Kingdom, Italy, Poland, Hungary, Denmark, Netherlands, Germany, Czechia, Portugal
-
Gannex Pharma Co., Ltd.CompletedPrimary Biliary CholangitisChina
-
Daiichi Sankyo, Inc.CompletedAtopic DermatitisUnited States
-
Cantex PharmaceuticalsRecruiting
-
Janssen-Cilag International NVCompleted
-
BioprojetCompletedParkinson's Disease | Excessive Daytime SleepinessFrance